CNBC's Meg Tirrell speaks to Acorda Therapeutics CEO Ron Cohen about Trump's comments against drug prices, and the current state of the biotech industry.
CNBC's Dominic Chu reports the latest on DOJ charges against Heritage Pharmaceuticals executives involving a generic drug pricing scheme.
Short-seller Andrew Left, Citron Research, discusses his tweet directing Donald Trump's attention towards Express Scripts, and his other shorts in the pharmaceutical space.
Short-seller Andrew Left, Citron Research, explains why Express Scripts is the "Philidor of the pharma industry," referring to Philidor Rx Services' alleged misconduct with Valeant Pharmaceuticals.
Shares of Express Scripts plunge following short-seller Andrew Left's series of tweets taking aim at the company. CNBC's Meg Tirrell reports.
Les Funtleyder, ESquared Asset Management, weighs in on Donald Trump's attack against drug prices, and the healthcare sector.
CNBC's Meg Tirrell reports on who may be leading the FDA under a Trump presidency.
Chris Meekins, FBR research analyst, discusses three reasons to ignore Donald Trump's comments against the current drug prices.
Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful.
CNBC’s Meg Tirrell talks to Kenneth Frazier, Merck CEO, at the fifth annual Forbes Healthcare Summit in New York about the future of drug pricing under the Trump administration as well as Alzheimer’s research.
Ravi Mehrotra, MTS Partners, and CNBC's Meg Tirrell discuss the high cost of pharmaceuticals in America and what can be done to rein prices in.
CNBC's Meg Tirrell speaks with Alkermes Chairman & CEO Richard Pops at the Partnering for Cures conference about drug pricing, his company's new depression drug and the opioid epidemic.
A study comparing three popular arthritis drugs shows they're all about equally safe and equally dangerous for the heart, reports NBC.
CNBC's Meg Tirrell reports the latest surrounding California's Proposition 61.
Bill George, Harvard Business School Professor and former Medtronic Chairman and CEO, and David Maris, Wells Fargo Securities Specialty Pharmaceutical Analyst, weigh in on the ongoing drug-pricing war.
CNBC's Meg Tirrell discusses the timeline on the war on drug pricing.
CNBC's Dominic Chu reports on possible charges being filed by the Justice Department against some generic drugmakers, according to Bloomberg.
Earnings are out for Gilead. CNBC's Meg Tirrell reports the details. “Fast Money” trader Jon Najarian weighs in.
Debating whether California voters should pass Proposition 61, the Drug Price Relief Act, with Scott Gottlieb, physician and American Enterprise Institute Resident Fellow, and Zeke Emanuel, University of Pennsylvania vice provost for global initiatives.
Jim Cramer addressed the stunning decline in McKesson, and got to the bottom of what triggered the sudden fall in the stock.